Molina Healthcare's Q4 Earnings Call: Our Top 5 Analyst Questions

Molina Healthcare’s fourth quarter results were marked by pronounced margin pressures, leading to a significant negative market reaction. Management attributed the underperformance to continued high medical cost trends in both Medicare and Marketplace, and unexpected retroactive adjustments in Medicaid, particularly in California. CEO Joseph Zubretsky described the quarter as disappointing, noting that “retroactive items in Medicaid totaled $2 per share,” and emphasized that elevated utilization across behavioral health services, long-term services and supports (LTSS), and high-cost drugs weighed on results. The company also highlighted that its Medicaid performance, while under pressure, remains above industry averages but was negatively impacted by these exceptional items.

Is now the time to buy MOH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Molina Healthcare’s Q4 Earnings Call

• Joshua Raskin (Nephron Research) asked about Medicaid margin variation by state and the causes of California’s retroactive adjustments. CEO Joseph Zubretsky detailed unique state actions and confirmed no plans to exit any state markets.
• A.J. Rice (UBS) questioned the company’s confidence in margin recovery for Medicaid post-2026. Zubretsky explained that margins remain positive even in the trough and expressed optimism for future equilibrium as states recognize underfunding.
• Justin Lake (Wolfe Research) pressed on the modest attrition assumptions for 2026 versus recent trends. Zubretsky and CFO Mark Keim provided a cohort analysis showing most low-utilization members have already left, making further negative acuity shifts less likely.
• Ann Hynes (Mizuho) inquired about the rationale behind the 5% cost trend assumption for 2026. Zubretsky provided a breakdown of behavioral health, pharmacy, and professional visit trends, emphasizing these are consistent with 2025 experience.
• Scott Fidel (Goldman Sachs) asked about the ROI and risks associated with new contract wins and M&A. Zubretsky and Keim acknowledged start-up losses on new contracts but underscored long-term earnings potential and the attractiveness of acquiring undervalued plans.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be watching (1) updates on Medicaid rate adjustments and any signs of moderation in medical cost trends, (2) execution on the Florida CMS contract launch and integration of any new acquisitions, and (3) the pace and impact of reducing Marketplace and MAPD exposure. Progress on margin stabilization and the company’s ability to win additional contracts will also be key markers for tracking Molina’s recovery trajectory.

Molina Healthcare currently trades at $123.19, down from $176.84 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.